Press release
Investors who lost money with shares of Organon & Co. (NYSE: OGN) should contact the Shareholders Foundation in connection with pending Lawsuit
A lawsuit was filed on behalf of investors in Organon & Co. (NYSE: OGN) shares over alleged securities laws violations.
Investors who purchased shares of Organon & Co. (NYSE: OGN) have certain options and for certain investors are short and strict deadlines running. Deadline: July 22, 2025. NYSE: OGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Jersey City, NJ based Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. Organon & Co. (NYSE: OGN) reported that its annual Total Revenue rose from over $6.23 billion in 2023 to over $6.4 billion in 2024, and that its Net Income declined from over $1.02 billion in 2023 to $864 million in 2024.
On May 1, 2025, Organon & Co. (NYSE: OGN) revealed that it was cuttings its dividend by approximately 90%.
Shares of Organon & Co. (NYSE: OGN) declined from $19.05 per share on October 31, 2024, to as low as $8.01 per share on May 14, 2025.
The plaintiff claims that between October 31, 2024, to April 30, 2025, the Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the Company's priorities, particularly, related to capital allocation through quarterly dividends, and that the Defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.
Those who purchased shares of Organon & Co. (NYSE: OGN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investors who lost money with shares of Organon & Co. (NYSE: OGN) should contact the Shareholders Foundation in connection with pending Lawsuit here
News-ID: 4043505 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Long-Term Investors in shares of The Bancorp, Inc. ( …
An investigation was announced for long-term investors in shares of The Bancorp, Inc. (NASDAQ: TBBK) concerning potential breaches of fiduciary duties by certain directors of The Bancorp, Inc.
Investors who are current long term investors in The Bancorp, Inc. (NASDAQ: TBBK) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Investors who lost money with shares of Krispy Kreme, Inc. (NASDAQ: DNUT) should …
An investor, who purchased shares of Krispy Kreme, Inc. (NASDAQ: DNUT), filed a lawsuit over alleged violations of Federal Securities Laws by Krispy Kreme, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Krispy Kreme, Inc. (NASDAQ: DNUT) have certain options and for certain investors are short and strict deadlines running. Deadline: July 15, 2025. NASDAQ: DNUT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors who lost money with shares of MicroStrategy Incorpor …
An investor, who purchased shares of MicroStrategy Incorporated (NASDAQ: STRK), filed a lawsuit over alleged violations of Federal Securities Laws by MicroStrategy Incorporated d/b/a Strategy.
Investors who purchased shares of MicroStrategy Incorporated (NASDAQ: STRK) have certain options and for certain investors are short and strict deadlines running. Deadline: July 15, 2025. NASDAQ: STRK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Tyson Corner, VA based MicroStrategy…
Lawsuit filed for Investors who lost money with shares of Iovance Biotherapeutic …
An investor, who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), filed a lawsuit i over alleged violations of Federal Securities Laws by Iovance Biotherapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have certain options and for certain investors are short and strict deadlines running. Deadline: July 14, 2025. NASDAQ: IOVA investors should contact the Shareholders Foundation at…
More Releases for Organon
Mirtazapine Tablets Market Analysis & Trends - Industry Forecast to 2027 |Novart …
LOS ANGELES, United States: The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global Mirtazapine Tablets market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Mirtazapine Tablets market. The authors of the report have segmented the global Mirtazapine Tablets market as per…
Mirtazapine Tablets Market To Witness Huge Growth By 20277- Novartis, Mylan, Org …
Complete study of the global Mirtazapine Tablets market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Mirtazapine Tablets industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also…
Ethinylestradiol Market Trend, Size, Share, Forecast 2021-2027 | Organon, Bayer, …
Ethinylestradiol market Research Report
LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, “Global Ethinylestradiol Market Report, History and Forecast 2016-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application“. This report offers an insightful take on the drivers and restraints present in the market. Ethinylestradiol data reports also provide a 5 year pre-historic and forecast for the sector and include data on socio-economic data…
Global Pinaverium Bromide Market Industry Analysis and Forecast 2015 - 2025, Sol …
Global Pinaverium Bromide is a medicine available in a number of countries worldwide. Pinaverium Bromide is a drug used for functional gastrointestinal disorders. It belongs to a drug group call antispasmodic and acts as a calcium channel blocker in helping to restore the normal contraction process of the bowel. It is most effective when taken for a full course of treatment and is not designed for immediate symptom relief or…
Global Pinaverium Bromide Market 2018: Key Players – Mylan, Organon, Solvay Ph …
Summary
WiseGuyReports.com adds “Pinaverium Bromide Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023 reports to its database.
Pinaverium Bromide is a medicine available in a number of countries worldwide. Pinaverium Bromide is a drug used for functional gastrointestinal disorders. It belongs to a drug group call antispasmodic and acts as a calcium channel blocker in helping to restore the normal contraction process of the bowel. It is most effective when…
Pinaverium Bromide Market 2017 - Mylan, SolvayPharmaceuticals, Organon, Solvay P …
Apex Research, recently published a detailed market research study focused on the "Pinaverium Bromide Market" across the global, regional and country level. The report provides 360° analysis of "Pinaverium Bromide Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Pinaverium Bromide industry, and estimates the future trend of Pinaverium Bromide market on…
